Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Drugs for Genetic Disease in Phase II Clinical Development in NETHERLANDS

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Khondrion

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              NETHERLANDS Netherlands

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              Khondrion Shares Progress of Sonlicromanol Development Programme at Mitochondrial Medicine 2020 Virtual Conference

              Contact the Supplier

              Lead Product(s): Sonlicromanol

              Therapeutic Area: Genetic Disease Product Name: KH176

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 27, 2020

              Details:

              An ongoing Phase 2B clinical trial in patients with MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) spectrum disorders is investigating the effect of sonlicromanol on cognitive functioning.

              Khondrion

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              NETHERLANDS Netherlands

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases

              Contact the Supplier

              Lead Product(s): Sonlicromanol

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 27, 2020

              Details:

              The study’s primary objective is to evaluate the dose-effect of Sonlicromanol on the attention domain score of cognitive functioning, Results are expected in the second half of 2020.

              PharmaCompass__DigitalAd